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Running Title:  Permacol™ collagen paste for anal fistula  
 
Abstract 
Aim: Permacol™ collagen paste (Permacol™ paste) is an acellular cross-linked porcine 
dermal collagen matrix suspension for use in soft tissue repair. The use of Permacol™ paste 
in the filling of anorectal fistula tract is a new sphincter-preserving method for fistula repair. 
The MASERATI100 study was a prospective, observational clinical study with the objective 
to assess the efficacy of Permacol™ collagen paste for anal fistula repair in 100 patients. 
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Method: Patients (N=100) with anal fistula were treated at ten European surgical sites with a 
sphincter-preserving technique using Permacol™ paste. Fistula healing was assessed at 1, 3, 
6, and 12 months post-treatment, with the primary endpoint being healing at 6 months. Faecal 
continence and patient satisfaction were surveyed at each follow-up; adverse events (AEs) 
were monitored throughout the follow-up. 
 
Results: At 6 months post-surgery, 56.7% of patients were healed, and the percentage healed 
was largely maintained, with 53.5% healed at 12 months. 29.0% of patients had at least one 
AE, and 16.0% of patients had one or more procedure-related AE. Most AEs reported were 
minor and similar to those commonly observed after fistula treatment, and the incidence of 
serious adverse events was low (4.0% of patients). Regardless of treatment outcome, 73.0% 
of patients were satisfied or very satisfied with the procedure. 
 
Conclusion: Permacol™ paste provides a promising sphincter-preserving treatment for anal 
fistulas with minimal adverse side-effects. 
 
ClinicalTrials.gov Identifier: NCT01624350 
Key Words: anal fistula, Permacol™ collagen paste, faecal continence, sphincter-preserving 
technique 
What does this paper add to the literature? (50 words max) 
This manuscript reports the final one year results of the one hundred patient cohort of the 
MASERATI100 study, the first study ever to assess the efficacy and safety of a sphincter 
preserving fistula repair technique using Permacol
TM
 collagen paste in the treatment of 
intersphincteric and transsphincteric primary and recurrent fistula.  
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Introduction 
Treatment options for repair and eradication of anal fistula bear the risk of 
postoperative faecal incontinence. Minimally invasive, sphincter-preserving treatments 
minimize risk of postoperative faecal incontinence, but success rates have been low [1-4]. 
Biological infill materials used to fill and close the fistula tract can support and promote 
tissue healing without damage to the sphincter muscle or surrounding tissue. Such materials 
include fibrin glue, a fistula plug composed of lyophilised porcine-derived small intestinal 
submucosa (Biodesign
®
 anal fistula plug, Cook Biotech Incorporated, West Lafayette, 
Indiana, USA), and autologous adipose cells, but their success rates vary widely [5-7]. 
Laying open the fistula tract of short intersphincteric fistulas is considered a relatively safe 
practice, but this method may still pose a small risk of faecal incontinence and wound 
complications [8]. Thus, the need for alternate treatment options is warranted. 
 
The core technology of Permacol
™
 collagen paste (Medtronic; Mansfield, MA, USA; 
henceforth, referred to as Permacol paste) is also the primary composition for Permacol
™
 
surgical implant (intended for soft tissue repair) and Permacol
™
 collagen injection (intended 
for filling and bulking indications). Permacol paste is a sterile suspension of acellular cross-
linked porcine dermal collagen matrix and saline. It may act as a scaffold to support cellular 
infiltration, promote tissue vascularization and enable fistula closure without damaging the 
anal sphincter.. As a paste, Permacol
TM
 is pliable and conforms to the unique shape of the 
fistula tract in contrast to  other implant materials which may be too liquid or rigid. 
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 The primary aim of the MASERATI100 clinical study was to assess anal fistula 
healing at 6 months using Permacol
TM
 paste.  The secondary aims were to evaluate fistula 
healing within one year, adverse events, pain, faecal continence, patient satisfaction, and 
quality of life.  This manuscript reports the completed one year study results including all 100 
patients enrolled from 10 investigative sites in Europe.  
 
Methods 
 The MASERATI100 study is a prospective, multi-centre, post-market, single-arm 
observational study on the use of Permacol
TM
 paste in the treatment of anal fistulas in 100 
patients. Ten European centres participated. This study received approval from both local and 
regional ethics committees and was conducted according to Good Clinical Practice (GCP) 
guidelines and with adherence to all European and national regulations. 
 
Study Participants 
 Patients with a clinical diagnosis of cryptoglandular anal fistula were invited to take 
participate. Inclusion and exclusion criteria have been  described in a previous study [9]. 
Patients with a solitary, primary or recurrent, transsphincteric or intersphincteric fistula tract 
of cryptoglandular origin were eligible. All underwent magnetic resonance imaging (MRI) of 
the perineum.  MRI scans were anonymised and assessed externally by one radiologist. If the 
operating surgeon deemed that the intraoperative findings met the inclusion criteria, the 
patient was included in the study and treated with Permacol
TM
 paste. Patients who gave 
informed consent but failed inclusion criteria or refused treatment were considered screen 
failures. Patients were reviewed at one, three, six, and 12 months following surgery.  
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Materials 
 Permacol
TM
 paste (Medtronic; Mansfield, MA) is contained within a sterile 3-mL 
syringe with a Luer-Lok connector. The milled collagen matrix suspension was injected into 
the fistula tract through a flexible cannula sheath (BD Angiocath™ 12GA; Becton Dickinson 
Medical Systems; Franklin Lakes, NJ, USA). Other materials used in the surgical procedure 
were standard and provided by the institution at which the patients were treated. 
Surgical Procedure 
 No other fistula surgery was to be performed between the MRI and treatment with 
Permacol
TM
 paste, apart from placement of a draining/loose seton if deemed appropriate. 
After pre-operative eligibility was confirmed, the surgeon proceeded with the surgery using 
standard surgical procedures based on training provided by the study sponsor. The 
requirement for bowel preparation was at the surgeon’s discretion. Examination under 
general anaesthesia was performed to confirm the patient’s suitability for the study. The 
internal and external fistula openings were identified. The “Instructions for Use” for 
Permacol
TM
 paste were followed, avoiding any dissection in or around the anal sphincter. 
Any seton was removed and then the fistula tract was de-epithelialised with a wire brush or 
equivalent to remove granulation tissue. The flexible cannula sheath was then inserted into 
the external opening of the fistula to the internal opening, which was closed by applying 
finger pressure  The paste was then injected to fill the tract completely (Figure 1). The tract 
was judged to be completely  filled when paste was visualised at both  internal and external 
openings. The internal opening was closed with a simple resorbable suture. The external 
opening was also loosely closed with an absorbable suture and this  allowed drainage of the 
fistula, but not extrusion of the paste. A sterile dressing was applied to the wound. Standard 
post-operative care was provided based on the routines adopted by each investigational site. 
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Outcome Measures 
 The primary endpoint was the rate of fistula healing at six months after surgery. 
Secondary outcome measures were safety, pain, faecal continence, patient satisfaction, and 
quality of life. 
 
Outcome Assessments 
 Patients were assessed for fistula healing and adverse events at one, three, six, and 12 
months by the investigating surgeon.  Fistula healing was defined as the absence of any anal 
symptom or discharge from the treated fistula with a closed external opening confirmed on 
clinical evaluation.. If a patient exited the study after the 3-month follow-up visit with a non-
healed fistula, that patient’s fistula was considered to be unhealed at the 6-month and 12-
month assessments.  Incidence and severity of adverse events (AEs) were recorded up to 12 
months. Pain was assessed using a 10-point Visual Analog Scale with the baseline at a 
screening visit prior to and within 60 days of scheduled surgery  It was reassessed at each 
follow-up visit.  Faecal continence was assessed before surgery and at each follow-up using 
the Cleveland Clinical Florida Faecal Incontinence (CCF-FI) questionnaire. At each follow 
up, patient satisfaction was measured by questionnaire and graded as “Very Satisfied,” 
“Satisfied,” “Dissatisfied,” or “Very Dissatisfied” via a questionnaire. The EQ-5D Quality of 
Life (QOL) score was assessed at baseline, three, six, and 12 months.  
Statistical Analysis 
 The sample size of the MASERATI100 clinical study was based on an expected 
healing rate of 60% and a two-sided 95.0% confidence interval for a single proportion 
extended to 10% on either side, with an assumed drop-out rate of 7% at six months. The final 
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sample size was determined to be 100 for the evaluable population, and the final analysis 
included all 100 patients treated.  Fistula healing was presented as the number and 
percentage of patients with a healed fistula at each of the follow-up visits, with a 95% 
confidence interval.. A chi-squared test or Fisher’s exact test was used to compare 
percentages of healing. Univariate and multivariate Cox regression analyses were performed 
to determine if any patient or fistula characteristic impacted fistula healing. The correlation 
between age and time taken to return to work and normal daily activities was analysed by a 
Spearman correlation test. CCF-FI scores and patient satisfaction were assessed at completion 
of the study: either the last visit before the exit in the case of patients who left the study early 
or the 12-month visit for the patients who completed the study. Differences in pain, CCF-FI 
score, and patient satisfaction from baseline to follow-up visits was compared by Wilcoxon 
signed rank tests or signed tests. The number and percentage of patients with an adverse 
event (AE) were analysed by severity and relationship to the paste or the procedure. All tests 
were two-sided and p <0.05 was considered statistically significant. All analyses were 
performed with SAS Version 9.2 (SAS Institute, Inc.; Cary, NC, USA).  
 
Results 
Participants and Procedural Characteristics 
One hundred out of 143 screened patients were enrolled in the MASERATI100 study 
between September 18, 2012 and February 5, 2014 with a median follow-up of 50 (1.6 – 
74.4) weeks. The median age of patients was 47.5 (range: ?   ) yrs.  The male to female ratio 
was 2.3:1 (Table 1). Fistula tracts ranged from 0.5 to 6.5 cm in length. Most (86%) patients 
had had previously undergone insertion of a loose seton, with median placement of 99 (14-
1437) days.  
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Granulation tissue was removed from most patients (93%) (Table 1). A single unit of 
the paste (≤3 mL PermacolTM paste) was sufficient to completely fill the fistula tract in 
96/100 patients. Duration of surgery was 21 (10 – 55) mins.  Although most patients (66%) 
were discharged on the day of the procedure, 29 stayed overnight, and five had a longer 
admission. The length of stay was influenced by the patient’s age, the time of the procedure 
and the patient’s proximity to the hospital. The median interval from the procedure to return 
to work and resume normal daily activity was 7 (1–35) days. 
 
A total of 75 patients completed follow-up to 12 months (Figure 2). In 24 patients 
who exited the study early, the fistula failed to heal at the final assessment (N=18) or the 
fistula recurred after an initial apparent healing (N=7).  Five patients exited the study at one 
month, 11 at three months, and eight at six months and were considered as unhealed at all 
subsequent follow-up time points. Only one patient was lost to follow-up after the three 
month visit and at that time the fistula had not healed.  
 
Efficacy of Permacol Paste 
Fistula healing is shown in Table 2. At 6 months post-surgery, 55 (56.7%; N=97) 
patients exhibited a clinically healed fistula. The healing rate was similar at both three 
months (53.2%; 50/94) and 12 months (53.5%; 53/99). The time to first healing, based on 
Kaplan-Meier estimates, was 76.0 days with a 95% confidence interval of 39.0–98.0 days. 
Most fistulae had healed within the first month. A total of 29 (29.0%) patients exhibited a 
recurrence within the 12 month follow-up. 
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Fistula healing at 12 months was associated with no 
PermacolTM
 paste extrusion, shorter 
fistula tract length (≤4 cm), and an intersphincteric fistula (Table 3).  Regression analysis did 
not confirm that intersphincteric fistulae were more likely to heal (Table 4).  Patients with no 
evidence of expulsion or leakage of Permacol
TM
 paste (P = 0.002) or shorter fistula tract 
length (P = 0.030) were more likely to heal (Table 4). Older patients and patients with a 
shorter time of seton implantation (among those with a previous seton) were also more likely 
to heal (P = 0.004 and 0.040, respectively). Patients with an anal abscess were more than four 
times more likely to experience treatment failure. Potential risk factors  such as diabetes, 
obesity, smoking status and previous failed treatments, including fistulotomy and  
fistulectomy,  did not influence the clinical outcome of Permacol
TM
paste injection. 
 
Adverse Events 
Twenty nine  patients experienced at least one Adverse Event (Table 5). AEs 
experienced by more than two patients included anal abscess, fistula tract infection, 
postoperative wound infection, procedural pain, and proctalgia. Four patients experienced 
Serious Adverse Events (SAEs) such as new anal fistula, anal abscess, procedural pain, and 
complex regional pain syndrome. Device-related AEs and procedure-related AEs occurred in 
16 (16.0%) patients. 
Pain, Faecal Continence, Patient Satisfaction and Quality of Life 
 At baseline (within 60 days prior to surgery), 29 (29.6%) patients were pain free, 
increasing to 45 (45.9%) at one month. At 12 months, 66 (89%) patients had only mild pain 
or no pain at all. Overall, mean patient pain was reduced (P < 0.001), relative to baseline, at 
all post-procedural follow-up assessments (Figure 3A).  
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 The mean CCF-FI score was significantly less (P<0.05) at the three, six, and 12 
month follow-up visits compared to the preoperative baseline assessment (Figure 3B), 
indicating improved faecal continence at these stages. The mean CCF-FI scores at all 
patients’ last visit, including scores for those 24 patients who exited the study early, was not 
significantly different from baseline.  
 
The EQ-5D QOL questionnaire results are reported in Figure 3C. Relative to baseline, 
significantly fewer subjects reported problems engaging in usual activities or experienced 
problems with anxiety and depression at the six month follow-up. Moreover, significantly 
fewer subjects had problems with motility and pain/discomfort at all follow-up visits 
compared to baseline.. 
 
A total of 85 patients completed the satisfaction survey in at least two follow-up 
visits. Patient satisfaction was assessed at each patient’s final visit in order to include patients 
who exited the study early with unhealed fistula. Regardless of healing status, 73.0% of 
patients (N=62) were satisfied or very satisfied with the procedure upon their last follow-up 
visit. 
 
Discussion 
This study suggests that Permacol
TM
 paste could be useful in managing anal fistula 
with healing rates of more than 50%, a low incidence of serious adverse events, and high 
patient satisfaction..  Fistula closure was fast with an average time to healing of just over two 
months. In fact, the majority of those who healed after 12 months had done so after one 
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month.  These final results are largely unchanged from the 54% healing rate of the initial 30 
patients reported previously from this study [9].  Pain levels were also satisfactory with 
87.7% of all patients experiencing none or mild pain after one month. 
 
The variety of procedures and biological materials available to treat anal fistula have 
shown unpredictable results (success rates of 16-85%), emphasizing the need for additional 
clinical data [10]. Too often studies reporting results of new modalities of treatment for 
fistula in ano have been based on a relatively small number of patients with limited follow up 
length from a single institution. A randomized control trial showed fistula healing rates of 
35.3% (N=51 patients) with fibrin glue and 54.8% (N=42 patients) with adipose-derived 
adult stem cells plus fibrin glue [11], and systemic reviews found healing rates ranging from 
16 - 92% for repairs with the anal fistula plug [5, 10, 12].   In many instances encouraging 
initial results have not been reproduced in subsequent studies and the variation in published 
outcome generates significant confusion. The MASERATI100 clinical study was designed to 
minimize any possible bias and produce reliable results reproducible in everyday clinical 
settings by recruiting patients in ten  centres across Europe. Healing was assessed on clinical 
grounds using the absence of symptoms and the presence of a healed external opening as a 
surrogate of healing. MRI was not used to measure healing because this was not carried out 
routinely for this purpose in participating centres, would have  added to the cost of the study. 
Furthermore there is no evidence as to what a healed fistula tract following collagen paste 
injection would look like on MRI. Prior to surgery,  MRI was used to assess the anatomy and 
initial complexity of the fistula and to assure that patients met the inclusion criteria.  
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The MASERATI100 study highlights several novel, previously unknown factors 
associated with successful healing with Permacol
TM
 paste. Patients with shorter fistula tracts 
were more likely to heal which is in contrast to the collagen fistula plug  where a longer tract 
has a more favourable outcome, possibly due to a lower displacement risk [13]. Fistula tract 
anatomy had no impact on healing, with similar rates for intersphincteric and transphincteric 
tracts. Perhaps the reduced healing observed in the longer tract is related to the resistance of 
the extrasphincterial tract to heal. If this is correct then a multi-step approach in patients with 
a long tract involving excision of the extrasphincterial  tract and then the use of the 
Permacol
TM
 paste at a later stage might improve overall healing rates..  
 
Consistent with the interim data, older patients were more likely to heal, a condition 
possibly attributable to differences in activity levels between younger and older patients. 
However, patient physical activity levels after treatment was not assessed in the study.  
 
Those patients who showed no evidence of paste expulsion were also more likely to 
heal. Treatment failure also occurred even when the implant remained, suggesting other  
biological factors may come in to play. Undetected sepsis and abscess formation has been 
previously implicated in treatment failure [14, 15], and indeed, patients treated with 
Permacol
TM
 paste were more than four times more likely to fail if they had an anal abscess. 
Other factors that may contribute to successful healing may be patient populations and 
comorbidities, bowel preparation regimens, variations of implant placement technique, suture 
materials used, and closure of the primary opening [5, 16, 17].  
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The actual nature of any implant material used for fistula surgery must impact on 
healing. Fibrin glue, for example, has a fluid consistency that hinders secure fixation of the 
glue within the track preventing proper sealing. The collagen fistula plug has a rigid structure 
which may lead to a poor fit and  extrusion as well a interfering with the healing process by 
leaving unrecognised secondary tracts untreated.  Surgisis® biomaterial (Cook Biotech), is 
non-cross-linked, possibly leading  to bacterial enzymatic degradation in complex 
environments [18]. In contrast, Permacol
TM
 paste is cross-linked and more readily resists 
enzymatic degradation while facilitating fibroblast and vascular ingrowth [18-20].  It is more 
pliable than a solid implant, allowing better conformation with the unique shape of fistula 
tracts and minimizing the risk of extrusion.  
 
As expected, Permacol
TM
 paste injection did not negatively impact faecal continence. 
In fact CCF-FI scores showed improvement in faecal continence, an observation that may be 
explained by a reduction of secretion rather than an improvement of sphincter function. 
While some adverse events were recorded, most were similar to those commonly observed 
after fistula treatment, such as anal abscess, new anal fistula, and procedural pain. The 
number of patients satisfied or very satisfied with the procedure at the last visit was greater 
than the number of patients healed, thus even patients in whom the treatment was not 
successful reported satisfaction. These results might reflect the benign nature of the 
procedure and therefore even a negative outcome is well accepted. A significant proportion of 
patients in the study had been previously exposed to more invasive treatments and failures, 
making the Permacol
TM
 paste injection a much more appealing option, possibly contributing 
to the very high satisfaction rate following this treatment modality.  
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The results of this final one-year analysis suggest that Permacol
TM
paste is a safe, 
minimally-invasive, sphincter-preserving treatment for anal fistulas, that promotes a good 
healing rate and is well perceived by patients. The lack of a comparative arm is an inherent 
limitation which we recognise.  However, the MASERATI100 study provides a useful 
assessment of the feasibility and safety of this technique and validates the rationale for future 
comparative studies between Permacol
TM
 paste and alternative interventions.  
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Table 1. Patient demographics, fistula characteristics, and operative details 
Parameter Permacol paste (N=100) 
Age 47.5 (20.0 – 78.0) 
Gender 100 
Female 30 
Male 70 
BMI (kg/m
2
) [1] 26.3 (16.4 – 46.2) 
Diabetes 2 
Smoking 26 
Steroids/Immunodepressants 4 
ASA score 1.0 (1 – 3) 
Recurrent fistula 39 
Fistula type per Parks’ Classification 100 
Intersphincteric 27 
Transsphincteric 73 
Extent of External Sphincter Involvement 73 
Greater than or Equal to 1/3 26 (35.6%) 
Less than 1/3 47 (64.4%) 
Level of Internal Opening 99 
Above Dentate Line 11 
At Dentate Line 66 
Below Dentate Line 22 
Length of Fistula Tract, cm 2.5 (0.5 – 6.5) 
Prior treatment of fistula with draining/loose seton 86 
Time between placement and removal of seton, days 99 (14 – 1437) 
Granulation tissue removed 93 (93%) 
Units of paste required per patient 100 
1 Unit 96 (96%) 
2 Units 4 (4%) 
Duration of operation (minutes) 21 (10 – 55) 
Data are expressed as n, n (%), or median (range). 
[1] BMI = Weight/(Height/100)
2 
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Table 2. Rate of fistula healing by visit   
  Permacol
TM
 paste (N=100) 
 Statistic 1 Month 3 Months 6 Months 12 Months 
Clinical assessment 
performed 
     
Yes n 99 89 81 75 
Missing n 1 6 3 1 
Exited from 
study 
n 0 5 16 24 
Clinically healed 
fistula [1] 
n/N (%) 47/99 (47.5) 50/94 (53.2) 55/97 (56.7) 53/99 (53.5) 
 95% CI 
37.3% – 
57.8% 
42.6% – 
63.6% 
46.3% – 
66.7% 
43.2% – 
63.6% 
[1] Data includes subjects whose assessment was performed and the final assessment of 
subjects who exited early from the study.  
 
 
 
 
Table 3. Sub-classification of fistula healing within 12 months 
 Paste extrusion/leakage 
Fistula healing No Yes P-value [1] 
Within 12 months N=72 N=27  
Yes 46 (63.9%) 7 (25.9%) <.001 
 Fistula tract length 
Fistula healing ≤4 cm >4 cm P-value [1] 
Within 12 months N=84 N=15  
Yes 51 (60.7%) 2 (13.3%) <.001 
 Fistula Parks classification 
Fistula healing Intersphincteric  Transsphincteric  P-value [1] 
Within 12 months N=27 N=72  
Yes 19 (70.4%) 34 (47.2%) 0.040 
Data shown as N, n (%), or p-value 
[1] P-value is from chi-square test (or fisher exact test) 
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Table 4. Relationship between patient/fistula characteristics and healing rate 
Variable 
p-value 
[1] 
Hazard Ratio  
(95% CI) 
Evidence of expulsion/leakage within the follow-up (ref = 
No) 
0.002* 3.133 (1.568-6.836) 
Fistula is a previously recurrent fistula (ref = No) 0.406 1.219 [0.769-1.963] 
Fistula Type per Parks’ Classification (ref = 
Transsphincteric) 
0.990 1.004 (0.534-1.943) 
Diabetes (ref = No) 0.414 1.930 (0.478-
13.077) 
Smoker (ref = No) 0.644 0.859 (0.454-1.661) 
Gender (ref = Male) 0.398 1.322 (0.703-2.584) 
Occurrence of AE = Anal Abscess (ref = No) 0.050 4.240 (1.257-
26.460) 
Length of Fistula Tract, cm 0.030* 0.742 (0.558-0.959) 
Age, yrs 0.004* 1.034 (1.011-1.059) 
BMI, kg/m
2
 0.176 0.961 (0.904-1.016) 
Time between placement and removal of seton 0.040* 0.999 (0.998-1.000) 
[1] P-value is from a multivariate Cox regression model (Full Analysis Set). 
* P < 0.05 
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Table 5. Device and procedure related AE and serious adverse events (SAEs) 
Variable Permacol
TM
 paste (N=48 AEs) 
Device and procedure related AE [1]  
 Anal abscess 4 (8.3%) 
 Anal fissure 1 (2.1%) 
 Anal fistula (new) 2 (4.2%) 
 Anal fistula infection, wound infection at the external 
fistula opening, or anal infection 
9 (18.8%) 
 Complex regional pain syndrome 1 (2.1%) 
 Eczema 1 (2.1%) 
 Haemorrhage 1 (2.1%) 
 Hypertrophic scar 1 (2.1%) 
 Procedural pain 3 (6.3%) 
 Proctalgia 7 (14.6%) 
 Tachycardia 1 (2.1%) 
Serious AE [1] 6 (12.5%) 
 Anal fistula 1 (1.0%) 
 Anal abscess 2 (2.0%) 
 Procedural pain 1 (1.0%) 
 Complex regional pain syndrome 1 (1.0%) 
 Pregnancy (Considered as SAE due to regulation)  1 (1.0%) 
Patients with at least 1 AE [2] 29 (29.0%) 
Patients with at least 1 SAE [2] 4 (4.0%) 
Patients with at least 1 device-related AE [2] 16 (16.0%) 
Patients with at least 1 procedure-related AE [2] 16 (16.0%) 
Data are expressed as n (%). 
[1] Percentages are based on the number of AEs in each category, N=48 AEs. 
[2] Percentages are based on the number of patients in the full analysis set. 
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Figure 1. Treatment of an anal fistula with Permacol
TM
 paste. Illustration of fistula 
morphology and the site of application of the paste. After debridement and cleaning of the 
fistula tract, the flexible cannula sheath is inserted into the external opening. The paste is 
applied to fill the fistula tract completely and both the internal and external openings are 
sutured. 
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Figure 2. Subject Flow. Shown is the number of subjects who were assessed at each post-
operative follow-up visit, excluding subjects who exited from the study before that follow-up 
visit. 
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Figure 3. Patient Pain, Faecal Continence, and Quality of life. (A) Pain levels were assessed 
on a VAS scale at the baseline visit (prior to the surgical procedure) and at each follow-up 
visit. Mean pain was significantly reduced (*P < 0.001) relative to baseline at all follow-up 
visits (P-values are from sign tests (3 Month – 12 Month) or Wilcoxon signed rank tests (1 
Month – 6 month). (B) Faecal continence was assessed at baseline, 3, 6, and 12 months, and 
at all patients’ last visit reached. The CCF-FI score was a combined assessment of the five 
types of incontinence; 0= Perfect; 20= Complete Incontinence. If a patient’s CCFI-FI 
assessment was incomplete then the CCF-FI score was not calculated for that visit. Mean 
CCF-FI faecal continence scores were significantly reduced from baseline at 3, 6, and 12 
months (*P<0.05 based on Wilcoxon signed rank tests (at 6 and 12 months) and sign test (3 
months). (C) The EQ-5D Quality of Life questionnaire assessed the percentage of subjects 
experiencing slight, moderate, severe, or extreme problems with particular factors that affect 
overall quality of life. N = 97, 88, 79, and 74 subjects who completed the questionnaire at 
baseline and 3, 6, and 12 months post-operatively, respectively. *P<0.05; **P<0.005, based 
on McNemar’s test for rates comparison between Month X and Baseline. 
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